CD47 and central nervous system cancer: Our study further reveals that CD47 can serve as a biomarker for patients with the GMC-I subtype of glioma, and modulating CD47 molecules may reverse the poor prognosis of the GMC-I subtype, providing guidance for clinical treatment.